Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients

Santosh Dhakal, Tong Yu, Anna Yin, Nora Pisanic, Zoe O. Demko, Annie Antar, Andrea Cox, Chris Heaney, Yukari C. Manabe, Sabra Klein

Research output: Contribution to journalArticlepeer-review

Abstract

Antinucleocapsid (anti-N) immunoglobulin G antibody responses were lower in plasma and oral fluid after severe acute respiratory syndrome coronavirus 2 infection in vaccinated patients compared with patients infected before vaccination or infected without vaccination. This raises questions about the long-term use of anti-N antibodies as a marker for natural infection for surveillance.

Original languageEnglish (US)
Article numberofac677
JournalOpen Forum Infectious Diseases
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2023

Keywords

  • COVID-19
  • hybrid immunity
  • nucleocapsid antibody
  • surveillance
  • vaccines

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients'. Together they form a unique fingerprint.

Cite this